Boehringer Ingelheim, the University of Oxford and Cumulus Neuroscience have launched a study to monitor brain activity in individuals with borderline personality disorder (BPD) using new technology.
The study will offer insights into the daily experiences of individuals with psychiatric disorders.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It aims to assess the acceptability of new technology designed to quantify the mood, behaviour and activity of the brain, and aid new therapeutic research and development.
The NeuLogiq neuroassessment platform from Cumulus will be leveraged in the BPD patient population for the first time.
It allows for brain function tracking over time, both in clinical settings and in patients’ homes.
The NeuLogiq headset enables individuals to engage in gamified versions of objective behavioural activities on a tablet.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe headset measures electroencephalogram (EEG) brain wave patterns that are accurately synchronised with the activities.
The goal is to capture data that offers a clearer understanding of the activity within the brain’s networks.
The Department of Psychiatry at the University of Oxford will carry out the study at Warneford Hospital, gathering frequent EEG and behavioural evaluations and remote metrics of mood and activity.
The study targets young adults aged 18 to 35 years and aims to evaluate the Cumulus platform’s feasibility in this population to offer a dataset for in-depth analysis of brain activity and behaviour in BPD.
30 BPD subjects and 20 subjects who have not been diagnosed with mental health disorders will be recruited.
Boehringer Ingelheim neuroscience and mental health global head and senior vice-president Dr Hugh Marston stated: “If this platform is successfully validated in this patient population, it could be a game-changer for studies investigating novel precision psychiatry treatments. It could help us identify biomarkers for stratification and provide a rich dataset for reverse translation.”
Boehringer recently entered a strategic research partnership with Cue Biopharma to develop and commercialise Cue’s CUE-501 product candidate for autoimmune conditions.
